SEC Form 4 · accession 0001237899-15-000032
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph L Goldstein
Director
Period of report
May 19, 2015
Accepted (ET)
May 20, 2015 · 4:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 19, 2015 | C | 20,000 | $0.00 | A | 24,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Class A StockF1,F2 | $0.00 | May 19, 2015 | C | 20,000 | D | — | — | Common Stock | 20,000 | 0 | D |
Explanation of responses
- F1Class A Stock of Regeneron Pharmaceuticals, Inc. ("Regeneron") converts to Common Stock of Regeneron on a one-to-one basis upon certain events or upon election of the shareholder.
- F2These shares of Class A Stock are presently convertible and such conversion feature does not expire.